PE20110116A1 - Asociacion de ivabradina y perindopril y composicion farmaceutica que la contiene - Google Patents

Asociacion de ivabradina y perindopril y composicion farmaceutica que la contiene

Info

Publication number
PE20110116A1
PE20110116A1 PE2010001026A PE2010001026A PE20110116A1 PE 20110116 A1 PE20110116 A1 PE 20110116A1 PE 2010001026 A PE2010001026 A PE 2010001026A PE 2010001026 A PE2010001026 A PE 2010001026A PE 20110116 A1 PE20110116 A1 PE 20110116A1
Authority
PE
Peru
Prior art keywords
ivabradine
perindopril
pharmaceutical composition
association
composition containing
Prior art date
Application number
PE2010001026A
Other languages
English (en)
Inventor
Vidal Benatar
Guy Lerebours-Pigeonniere
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36685870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20110116A1 publication Critical patent/PE20110116A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR SELECTIVO DE LA CORRIENTE SINUSAL TAL COMO IVABRADINA EN FORMA DE SAL DE HIDROCLORURO, SUS HIDRATOS O FORMAS CRISTALINAS; B)UN AGENTE INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA TAL COMO PERINDOPRIL EN FORMA DE SAL TERCBUTILAMINA O DE ARGININA Y UNO O VARIOS EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL
PE2010001026A 2005-12-21 2006-12-18 Asociacion de ivabradina y perindopril y composicion farmaceutica que la contiene PE20110116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0513006A FR2894825B1 (fr) 2005-12-21 2005-12-21 Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20110116A1 true PE20110116A1 (es) 2011-03-02

Family

ID=36685870

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010001026A PE20110116A1 (es) 2005-12-21 2006-12-18 Asociacion de ivabradina y perindopril y composicion farmaceutica que la contiene
PE2006001619A PE20071004A1 (es) 2005-12-21 2006-12-18 Composiciones farmaceuticas que comprenden la combinacion de ivabradina y perindropil

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2006001619A PE20071004A1 (es) 2005-12-21 2006-12-18 Composiciones farmaceuticas que comprenden la combinacion de ivabradina y perindropil

Country Status (42)

Country Link
US (2) US20070142355A1 (es)
EP (2) EP1800678B1 (es)
JP (2) JP4705564B2 (es)
KR (2) KR100907583B1 (es)
CN (1) CN101015557B (es)
AP (1) AP2119A (es)
AR (1) AR058574A1 (es)
AT (1) ATE508742T1 (es)
AU (1) AU2006252210B2 (es)
BR (1) BRPI0605517A (es)
CA (1) CA2571644C (es)
CO (1) CO5790168A1 (es)
CR (1) CR8820A (es)
CY (1) CY1111575T1 (es)
DK (1) DK1800678T3 (es)
EA (1) EA011253B1 (es)
ES (1) ES2366570T3 (es)
FR (1) FR2894825B1 (es)
GE (1) GEP20094604B (es)
GT (1) GT200600522A (es)
HK (1) HK1106444A1 (es)
HR (1) HRP20110532T1 (es)
IL (1) IL180204A (es)
JO (1) JO2699B1 (es)
MA (1) MA28723B1 (es)
ME (1) ME01958B (es)
MX (1) MXPA06014885A (es)
MY (1) MY146956A (es)
NO (1) NO337640B1 (es)
NZ (1) NZ552221A (es)
PE (2) PE20110116A1 (es)
PL (1) PL1800678T3 (es)
PT (1) PT1800678E (es)
RS (1) RS51731B (es)
SA (1) SA06270480B1 (es)
SG (2) SG173243A1 (es)
SI (1) SI1800678T1 (es)
TW (1) TWI369206B (es)
UA (1) UA86417C2 (es)
UY (1) UY30023A1 (es)
WO (1) WO2007077327A1 (es)
ZA (1) ZA200610824B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
CN101564394B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 含有伊伐布雷定和曲美他嗪的药物组合物
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013116738A1 (en) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Drug formulations
FR3050380B1 (fr) 2016-04-20 2020-07-10 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2449934A1 (en) * 2001-06-08 2002-12-19 Ortho-Mcneil Pharmaceutical, Inc. Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
AR036187A1 (es) * 2001-07-24 2004-08-18 Adir Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
KR100907583B1 (ko) 2009-07-14
JO2699B1 (en) 2013-03-03
ATE508742T1 (de) 2011-05-15
NO20065905L (no) 2007-06-22
SI1800678T1 (sl) 2011-08-31
PT1800678E (pt) 2011-07-12
SA06270480B1 (ar) 2011-02-23
IL180204A (en) 2014-02-27
ES2366570T3 (es) 2011-10-21
EA200602155A1 (ru) 2007-08-31
EP1800678B1 (fr) 2011-05-11
CN101015557B (zh) 2010-12-08
HK1106444A1 (en) 2008-03-14
AP2119A (en) 2010-04-21
JP2007169283A (ja) 2007-07-05
HRP20110532T1 (hr) 2011-08-31
ZA200610824B (en) 2008-06-25
PE20071004A1 (es) 2007-11-17
ME01958B (me) 2011-10-31
TWI369206B (en) 2012-08-01
AU2006252210A1 (en) 2007-07-05
EA011253B1 (ru) 2009-02-27
KR20090047424A (ko) 2009-05-12
KR20070066921A (ko) 2007-06-27
MA28723B1 (fr) 2007-07-02
CN101015557A (zh) 2007-08-15
DK1800678T3 (da) 2011-08-15
GT200600522A (es) 2007-07-25
CR8820A (es) 2007-08-28
GEP20094604B (en) 2009-02-10
AU2006252210B2 (en) 2012-04-26
EP1800678A1 (fr) 2007-06-27
PL1800678T3 (pl) 2011-08-31
CY1111575T1 (el) 2015-10-07
IL180204A0 (en) 2008-01-20
NO337640B1 (no) 2016-05-23
CO5790168A1 (es) 2007-08-31
CA2571644A1 (fr) 2007-06-21
US20120196850A1 (en) 2012-08-02
CA2571644C (fr) 2011-03-08
MXPA06014885A (es) 2009-02-11
FR2894825B1 (fr) 2010-12-03
SG173243A1 (en) 2011-08-29
BRPI0605517A (pt) 2007-10-16
UA86417C2 (ru) 2009-04-27
RS51731B (en) 2011-10-31
NZ552221A (en) 2008-05-30
JP2011079854A (ja) 2011-04-21
TW200744608A (en) 2007-12-16
AR058574A1 (es) 2008-02-13
UY30023A1 (es) 2007-01-31
WO2007077327A1 (fr) 2007-07-12
JP4705564B2 (ja) 2011-06-22
MY146956A (en) 2012-10-15
FR2894825A1 (fr) 2007-06-22
EP2298297A1 (fr) 2011-03-23
SG133545A1 (en) 2007-07-30
US20070142355A1 (en) 2007-06-21
AP2006003859A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
PE20110116A1 (es) Asociacion de ivabradina y perindopril y composicion farmaceutica que la contiene
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
CL2012001328A1 (es) Compuestos derivados de (4,5,6,7-tetrahidro-1h-indazol-3-il)-1h-indol, inhibidores de itk; composicion farmaceutica; utiles en el tratamiento de enfermedades inflamatorias, tales como artritis reumatoidea, alergias, enfermedades autoinmunes, entre otras.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
PE20150202A1 (es) Compuestos antivirales
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
CL2011002862A1 (es) Uso de perhexilina o una sal farmaceuticamente aceptable de la misma para preparar un medicamento util en el tratamiento de miocardiopatia hipertrofica (mch).
PE20120019A1 (es) Combinacion de perindopril y n-{[(7s)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil}-3-(7,8-dimetoxi-1,2,4,5-tetrahidro-3h-3-benzazepin-3-il)-n-metil-3-oxo-1-propanamina
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2007001910A1 (es) Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
EA200602156A1 (ru) Новая комбинация ингибитора iтока синусового узла и кальциевого ингибитора и фармацевтические композиции, её содержащие
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
GT200800178A (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina
EA201100132A1 (ru) Единичная доза ападеносона
NO20071330L (no) Enzyminhibitor i leukemi
UY31856A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antiflamatorio, no esteroideo y un derivado de colchicosido
MY154024A (en) Oral care compositions and methods
CL2007003834A1 (es) Compuestos derivados de s-nitrosotiol; procedimiento de sintesis; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades mediadas por el oxido nitrico tales como hipertension, trombosis, entre otras.

Legal Events

Date Code Title Description
FC Refusal